Premium
Metoprolol CR/XL in the Treatment of Chronic Heart Failure
Author(s) -
Gattis Wendy A.
Publication year - 2001
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.21.6.604.34551
Subject(s) - metoprolol , metoprolol tartrate , medicine , heart failure , drug , pharmacodynamics , pharmacokinetics , pharmacology , cardiology
Metoprolol CR/XL (metoprolol succinate extended‐release tablets) is a β 1 ‐selective agent that improved survival and reduced hospitalization among patients with New York Heart Association class II‐IV heart failure in a randomized trial. Metoprolol CR/XL differs from conventional metoprolol tartrate with respect to pharmacokinetic and pharmacodynamic properties that may be clinically important in patients with heart failure. A thorough patient evaluation should be performed to determine optimal dosage and titration of this drug, as with any β‐blocker, and to assess the potential for drug‐drug or drug‐disease interactions. By applying knowledge of drug‐specific characteristics and designing therapy for each individual patient, improvement in patient outcomes can be realized with metoprolol CR/XL.